A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients

Not Applicable

Recruiting

• Conditions: Treatment-resistant Depression; Persistent Depressive Disorder
• Interventions: Behavioral: inpatient CBASP individual therapy; Behavioral: inpatient BA individual therapy; Behavioral: inpatient BA group therapy; Behavioral: inpatient CBASP group therapy; Behavioral: inpatient BA nurse contact; Behavioral: inpatient CBASP nurse contact; Behavioral: inpatient CBASP exercise therapy; Behavioral: inpatient BA exercise therapy; Behavioral: outpatient CBASP group therapy; Behavioral: outpatient BA group therapy; Drug: algorithm-based study medication

• Registration Number: NCT04996433
• Lead Sponsor: University of Greifswald

Brief Summary

The purpose of this study is to compare the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) conducted over 16 weeks (acute and continuation treatment) with Behavioral Activation (BA; same dose and duration) in persistently depressed treatment-resistant inpatients regarding efficacy, moderators and mediators of change.

Detailed Description

About half of all psychiatric inpatients with depression suffer from persistent depressive disorder (PDD). Given their high degree of treatment-resistance (TR), comorbidity, suicidality, and hospitalization rates, this patient group appears to be particularly difficult to treat and, from a health economic perspective, constitutes a major challenge. The Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is the only psychotherapy specifically tailored for PDD developed. Originally developed as an outpatient treatment by James P. McCullough, CBASP has been modified for the severely ill PDD patients with TR as a multimodal inpatient concept. Pilot studies indicate very good feasibility and promising outcome. Therefore, a randomized controlled trial is now mandatory for testing the superiority of the inpatient CBASP program vs. the evidence-based Cognitive Behavioral Therapy (CBT), the 'gold standard' in depression treatment. Behavioral Activation (BA) was chosen as the control intervention because BA, as a specific variant of CBT, is at least as effective as standard CBT in severely depressed patients while being easier to train and implement in inpatient settings. Both therapies will be applied as a treatment-phase program (5-week inpatient and dayclinic acute treatment followed by 6-week outpatient continuation group-treatment) in combination with standardized and guideline-based pharmacotherapy. The proposed prospective, multi-center, randomized study with 396 PDD patients with TR will therefore address the primary research question: Is the CBASP program more effective than the BA program in this patient group? The primary hypothesis is that after 16 weeks of treatment, CBASP will show a significant superiority over BA in reducing depressive symptoms. In addition, the important psychotherapy research question: what works for whom and why? will be addressed.

Moderator analyses will examine whether childhood maltreatment and methylation of exon IV of the BDNF gene have an impact on the differential efficacy of the treatments. Regarding mediator analyses, it will be examined whether symptom improvements can be explained by an amelioration of interpersonal problems in CBASP and an increase of activity levels in BA. A follow-up survey 48 weeks after the end of the interventions will provide valuable results regarding the long-term outcome of the treatments. Finally, the health economic potential of the interventions will be investigated through cost-benefit analyses in order to provide important information on the cost-effectiveness of implementation in routine care for health policy. Thus, the results of this study will have the potential to relieve the burden of this very serious and cost-intensive disorder while improving human health. In addition, moderator and mediator analyses may guide personalized treatment and enable therapists to more specifically address psychotherapeutic needs of individual PDD patients in the future.

Study Timeline

• Study First Submitted: 2021-06-27
• Study First Submitted QC: 2021-07-30
• Study First Posted: 2021-08-09
• Study Start: 2021-12-01
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-10
• Last Update Posted: 2023-10-12
• Primary Completion: 2024-07
• Study Completion: 2026-05

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 396

Inclusion Criteria

• Primary DSM-5 diagnosis of PDD (300.4, 296.2x, 296.3x)
• Total Hamilton Depression Rating Scale (HDRS-24) Score ≥ 20
• Treatment-resistance (TR) (defined as a level of 3 or higher on the Antidepressant Treatment History Form: Short Form (ATHF-SF) or medication intolerance or one psychotherapy at least 25 sessions by a certified therapist in the current episode)
• Sufficient knowledge of the German language
• Written informed consent

Exclusion Criteria

• Bipolar I or II disorder
• Active substance use disorders (abstinence shorter than 6 months)
• Schizophrenia spectrum and other psychotic disorders
• Antisocial personality disorder
• Acute suicidality
• Previous CBASP or BA treatment within the last year
• Inability to tolerate CBASP or BA (e.g., organic brain disorders, severe cognitive deficits)
• Inability to participate in dayclinic or outpatient continuation treatment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cognitive Behavioral Analysis System of Psychotherapy (CBASP)	inpatient CBASP individual therapy	Cognitive Behavioral Analysis System of Psychotherapy (CBASP) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
Cognitive Behavioral Analysis System of Psychotherapy (CBASP)	inpatient CBASP exercise therapy	Cognitive Behavioral Analysis System of Psychotherapy (CBASP) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
Cognitive Behavioral Analysis System of Psychotherapy (CBASP)	outpatient CBASP group therapy	Cognitive Behavioral Analysis System of Psychotherapy (CBASP) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
Behavioral Activation (BA)	inpatient BA group therapy	Behavioral Activation (BA) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
Behavioral Activation (BA)	inpatient BA nurse contact	Behavioral Activation (BA) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
Behavioral Activation (BA)	inpatient BA exercise therapy	Behavioral Activation (BA) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
Behavioral Activation (BA)	inpatient BA individual therapy	Behavioral Activation (BA) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
Behavioral Activation (BA)	outpatient BA group therapy	Behavioral Activation (BA) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
Cognitive Behavioral Analysis System of Psychotherapy (CBASP)	inpatient CBASP group therapy	Cognitive Behavioral Analysis System of Psychotherapy (CBASP) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
Cognitive Behavioral Analysis System of Psychotherapy (CBASP)	inpatient CBASP nurse contact	Cognitive Behavioral Analysis System of Psychotherapy (CBASP) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
Behavioral Activation (BA)	algorithm-based study medication	Behavioral Activation (BA) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
Cognitive Behavioral Analysis System of Psychotherapy (CBASP)	algorithm-based study medication	Cognitive Behavioral Analysis System of Psychotherapy (CBASP) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).

Primary Outcome Measures

Name	Time	Method
Hamilton Depression Rating Scale (HDRS-24), 24-item version	16 weeks	The change in HDRS-24 item score after 16 weeks will be the primary endpoint. The HRSD-24 is a semi-structured interview which is used to measure the severity of all symptom domains of depression as described by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) over a period of the last 7 days. It shows good psychometric properties. The HRSD-24 will be conducted by blind study raters at every time point. Raters evaluate symptom severity on a scale from 0 to 2 or 0 - 3 or 0 - 4 for each item, with higher number indicating higher symptom severity. The total score ranges from 0 to 75 with higher values indicating higher depression severity.

Secondary Outcome Measures

Name	Time	Method
Response	baseline, weeks 1, 5, 10, 16, 64	Response (50% decrease on HDRS-24 score)
Cost interview	baseline, weeks 16 and 64	The cost interview assesses direct medical and non-medical costs and indirect costs due to mental disorders versus physical illnesses.
Relapse rates	16, 64	Relapse rates (rehospitalization, increase of HDRS-24 of equal or greater than 10 or current HDRS-24 score of equal or greater than 18 points) are measured.
Hamilton Depression Rating Scale (HDRS-24), 24-item version	baseline, weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 64	The HDRS-24 is a semi-structured interview which is used to measure the severity of all symptom domains of depression as described by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) over a period of the last 7 days. It shows good psychometric properties. The HDRS-24 will be conducted by blind study raters at every time point. Raters evaluate symptom severity on a scale from 0 to 2 or 0 - 3 or 0 - 4 for each item, with higher number indicating higher symptom severity. The total score ranges from 0 to 75 with higher values indicating higher depression severity.
Brief Symptom Inventory (BSI)	baseline, weeks 1, 5, 10, 16, 64	The BSI is a multi-dimensional self-reported measure with a total of nine scales assessing the subjective impairment by physical and psychological symptoms. Each item is rated on a scale from 0 to 5 by the patient and are added up and t-transformed to three global indices: Global Severity Index, Positive Symptom Distress Index, Positive Symptom Total. T-Scores range from 0 to 100, with higher values indicating a higher subjective impairment.
World Health Organization Quality of Life (WHOQoL-BREF)	baseline, weeks 1, 5, 10, 16, 64	The WHOQoL-BREF is a self-reporting measure regarding the subjective quality of life. Four broad domains of quality of life are rated by the patient on a five point scale and a mean score for each domain is calculated. Scores range between 4 and 20, with a higher score indicating a higher quality of life and therefore a better outcome.
Remission	baseline, weeks 1, 5, 10, 16, 64	Remission (HDRS-24 score of 10 or less)
Global Assessment of Functioning (GAF)	baseline, weeks 1, 5, 10, 16, 64	The GAF is a diagnostic measure used to assess social, occupational and psychological functioning according to DSM-IV. The score ranges from 0 to 100 with a total of ten levels of functioning and is determined by a clinical rater. Higher scores indicate a higher level of functioning and therefore a better outcome.
Inventory of Depressive Symptomatology, Self-Report (IDS-SR)	baseline, weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 32, 40, 48, 56, 64	The IDS-SR is a self-reported measure of depressive symptoms and used to detect change in self-rated depression severity. It shows good psychometric properties. Each item is rated from 0 to 3 by the patient, and all values are added up to an overall score. Total score ranges from 0 to 78, with higher values indicating a higher depression severity.

Trial Locations

Locations (6)

Universität zu Lübeck; 🇩🇪 Lübeck, Germany

Charité, University Medicine Berlin; 🇩🇪 Berlin, Germany

Klinikum der Universität München; 🇩🇪 München, Germany

Universitätsklinikum Tübingen; 🇩🇪 Tübingen, Germany

Universitätsklinikum Marburg; 🇩🇪 Marburg, Germany

Medizinische Hochschule Hannover; 🇩🇪 Hannover, Germany